At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 252 enrolled
Drug / intervention
Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)drug
Likely dose
Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing) 0.120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Contraceptive Vaginal Ring Releasing Etonogestrel and Ethinylestradiol (NuvaRing): Cycle Control, Acceptability and Tolerability Study in Indian Women
In Brief
A Phase 4 clinical trial evaluating Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing) for Contraception. Completed, enrolled 252 participants.
Detailed Summary
This study will collect information on cycle control, acceptability and tolerability of the vaginal contraceptive ring (NuvaRing) as used in normal daily practice by Indian women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartDec 2011
Primary CompletionDec 2012
TodayJul 2026
First PostedDec 12, 2011
Enrollment StartDec 26, 2011
Primary CompletionDec 5, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.6 years ago
Interventions
Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)drug
Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.